Curi RMB Capital LLC Makes New $246,000 Investment in Solventum Co. (NYSE:SOLV)

Curi RMB Capital LLC bought a new stake in Solventum Co. (NYSE:SOLV) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,534 shares of the company’s stock, valued at approximately $246,000.

A number of other hedge funds have also made changes to their positions in SOLV. Davis Selected Advisers acquired a new stake in Solventum during the 2nd quarter valued at $273,070,000. Nuance Investments LLC purchased a new stake in shares of Solventum in the second quarter valued at $115,829,000. Newport Trust Company LLC acquired a new stake in shares of Solventum during the second quarter valued at $98,976,000. Baupost Group LLC MA purchased a new stake in Solventum during the 2nd quarter worth about $96,242,000. Finally, Magnetar Financial LLC raised its stake in Solventum by 2,880.8% in the 2nd quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company’s stock valued at $78,813,000 after purchasing an additional 1,440,410 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SOLV shares. Piper Sandler raised their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. The Goldman Sachs Group raised their target price on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research report on Monday, August 12th. BTIG Research assumed coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating for the company. Morgan Stanley raised their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Wells Fargo & Company dropped their target price on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $68.00.

Solventum Stock Down 0.6 %

Shares of NYSE SOLV opened at $67.48 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a fifty day moving average of $70.54 and a 200-day moving average of $62.22. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.